Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CC-1088 in Myelodysplastic Syndromes
NCT00045786Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2001
- Primary completion
- Dec 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CDC-801 in myelodysplastic syndrome (MDS) (4 arms), sponsored by Celgene Corporation. Primary endpoint: Safety of CC-1088. Started Oct 2001; status: completed.
02
Drugs
CDC-801
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00045786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045786.